Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RV 507: cAd3-Marburg Vaccine in Healthy Adults
NCT03475056Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2018
- Primary completion
- Dec 2019
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChAd3-MARV in Marburg virus disease (MVD) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms at 7 days, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms at 7 days and 4 more. Started Oct 2018; status: completed.
02
Drugs
ChAd3-MARV
03
Conditions
Marburg virus disease (MVD)
Beyond the preview
Go deeper on NCT03475056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03475056.